{
    "organizations": [],
    "uuid": "bdee492157572d11e36089145ec692c5be8bd249",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-immunogen-announces-positive-findi/brief-immunogen-announces-positive-findings-from-forward-2-study-of-mirvetuximab-soravtansine-combination-regimens-idUSFWN1SN0YT",
    "ord_in_thread": 0,
    "title": "BRIEF-Immunogen Announces Positive Findings From Forward 2 Study Of Mirvetuximab Soravtansine Combination Regimens",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - ImmunoGen Inc:\n* IMMUNOGEN ANNOUNCES POSITIVE FINDINGS FROM THE FORWARD II STUDY OF MIRVETUXIMAB SORAVTANSINE COMBINATION REGIMENS WITH AVASTINÂ® AND CARBOPLATIN IN OVARIAN CANCER\n* IMMUNOGEN - UPDATED DATA FROM CARBOPLATIN DOSE-ESCALATION COHORT DEMONSTRATE INCREASED RESPONSE RATE AND DURABLE BENEFIT WITH LONGER-TERM FOLLOW UP Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-17T05:16:00.000+03:00",
    "crawled": "2018-05-17T14:40:30.018+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "immunogen",
        "inc",
        "immunogen",
        "announces",
        "positive",
        "finding",
        "forward",
        "ii",
        "study",
        "mirvetuximab",
        "soravtansine",
        "combination",
        "regimen",
        "carboplatin",
        "ovarian",
        "cancer",
        "immunogen",
        "updated",
        "data",
        "carboplatin",
        "cohort",
        "demonstrate",
        "increased",
        "response",
        "rate",
        "durable",
        "benefit",
        "follow",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}